株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

男性不妊症:パイプライン製品の分析

Male Infertility - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 255962
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
男性不妊症:パイプライン製品の分析 Male Infertility - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 38 Pages
概要

男性不妊症とは、繁殖可能な女性を妊娠させる能力が男性側にない状態のことを指します。男性不妊症は造精機能障害や精子無力症、射精障害などが原因で発症します。主な症状として、睾丸周辺の痛みや腫れ、しこりなどが挙げられます。主な疾患素質として、喫煙や飲酒、体重超過、毒素への曝露、特定の疾患(腫瘍・慢性病ほか)などが考えられています。主な治療法には、外科手術やホルモン補充治療などがあります。

当レポートでは、世界各国での男性不妊症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

男性不妊症の概要

治療薬の開発

  • 男性不妊症向けパイプライン製品:概要
  • 各企業で開発中の男性不妊症治療薬
  • 大学/研究機関で研究中の男性不妊症治療薬
  • 開発中の製品の一覧(企業別)
  • 研究中の製品の一覧(大学/研究機関別)

男性不妊症:治療薬の評価

  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

男性不妊症治療薬の開発に従事している企業

  • AlphaMab Co Ltd
  • Ferring International Center SA
  • Health Ever Bio-Tech Co Ltd
  • Navya Biologicals Pvt Ltd
  • PharmaEssentia Corp
  • TocopheRx Inc
  • Zydus Cadila Healthcare Ltd

薬剤のプロファイル

男性不妊症治療薬:開発が休止状態の製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9131IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Infertility - Pipeline Review, H1 2017, provides an overview of the Male Infertility (Male Health) pipeline landscape.

Male infertility refers to a male's inability to achieve a pregnancy in a fertile female. Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Infertility - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Male Infertility - Overview
    • Male Infertility - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Male Infertility - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Male Infertility - Companies Involved in Therapeutics Development
    • AlphaMab Co Ltd
    • Ferring International Center SA
    • Health Ever Bio-Tech Co Ltd
    • Navya Biologicals Pvt Ltd
    • PharmaEssentia Corp
    • TocopheRx Inc
    • Zydus Cadila Healthcare Ltd
  • Male Infertility - Drug Profiles
    • Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 5 for Infertility and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FE-999310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-FSH - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Beta Glucosidase 2 Replacement for Gaucher's Disease and Male Infertility - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trequinsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Male Infertility - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Male Infertility, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Male Infertility - Pipeline by AlphaMab Co Ltd, H1 2017
  • Male Infertility - Pipeline by Ferring International Center SA, H1 2017
  • Male Infertility - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017
  • Male Infertility - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
  • Male Infertility - Pipeline by PharmaEssentia Corp, H1 2017
  • Male Infertility - Pipeline by TocopheRx Inc, H1 2017
  • Male Infertility - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Male Infertility - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Male Infertility, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top